Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 season

Trial Identifier: D2560C00014
Sponsor: MedImmune, LLC
Collaborator:
AstraZeneca
NCTID:: NCT03158038
Start Date: May 2017
Primary Completion Date: December 2017
Condition: Healthy Volunteers; Influenza Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation

Trial Locations

Country Location
United States of America, GA Stockbridge, GA, United States of America, 30281
United States of America, OR Portland, OR, United States of America, 97239